Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Lilly

21:21 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Lilly" found in our extensive news archives from over 250 global news sources.

More Information about Lilly on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Lilly for you to read. Along with our medical data and news we also list Lilly Clinical Trials, which are updated daily. BioPortfolio also has a large database of Lilly Companies for you to search.

Showing News Articles 1–25 of 62 from Lilly

Friday 9th March 2018

Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology

Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology

Thursday 8th March 2018

EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research

EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research

Tuesday 6th March 2018

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials

Monday 26th February 2018

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

Wednesday 21st February 2018

Lilly to Participate in Barclays Global Healthcare Conference

Lilly to Participate in Barclays Global Healthcare Conference

Tuesday 20th February 2018

Lilly to Participate in Cowen Health Care Conference

Lilly to Participate in Cowen Health Care Conference

Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month

Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month

Monday 19th February 2018

AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

Wednesday 14th February 2018

Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting

Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting

Tuesday 13th February 2018

Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Wednesday 31st January 2018

Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance

Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance

Friday 26th January 2018

Lilly To Present At Leerink Partners Global Healthcare Conference

Lilly To Present At Leerink Partners Global Healthcare Conference

Monday 8th January 2018

Livongo and Lilly Collaborate on Real-World Diabetes Research

Livongo and Lilly Collaborate on Real-World Diabetes Research

Friday 5th January 2018

Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement

Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement

Monday 18th December 2017

Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference

Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference

Thursday 14th December 2017

Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin

Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin

Wednesday 13th December 2017

Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020

Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020

Monday 11th December 2017

Lilly Announces 8 Percent Dividend Increase

Lilly Announces 8 Percent Dividend Increase

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults

Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology

Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology

Friday 8th December 2017

Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

Tuesday 5th December 2017

Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System

Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System

Friday 1st December 2017

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks